Drug Trial Radar · NCT05461170
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
95
Actual
Start
Sep 17, 2022
Primary completion
Nov 2031
Study completion May 2032
Sponsor
- Lead sponsor
- Vir Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy
Conditions
- Hepatitis D, Chronic
Interventions
VIR-2218Drug
VIR-2218 given by subcutaneous injection
VIR-3434Drug
VIR-3434 given by subcutaneous injection
NRTIDrug
NRTI given orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with undetectable HDV RNA (< limit of detection [LOD]) or ≥ 2 log10 decrease in HDV RNA from baseline and alanine aminotransferase (ALT) normalization (ALT < upper limit of normal [ULN]) at Week 24Time frame: Up to 24 Weeks
- Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Up to 360 Weeks
Locations
20 sites in 9 countries. Site status is shown where the registry gives one.
Investigative Site
Sofia, Bulgaria
Investigative Site
Sofia, Bulgaria
Investigative Site
Stara Zagora, Bulgaria
Investigative Site
Clichy, France
Investigative Site
Pessac, France
Investigative Site
Rennes, France
Investigative Site
Toulouse, France
Investigative Site
Frankfurt, Germany
Investigative Site
Hanover, Germany
Investigative Site
Tübingen, Germany
Investigative Site
Milan, Italy
Investigative Site
Pisa, Italy
Investigative Site
Chisinau, Moldova
Investigative Site
Rotterdam, Netherlands
Investigative Site
Auckland, New Zealand
Investigative Site
Bucharest, Romania
Investigative Site
Birmingham, United Kingdom
Investigative Site
London, United Kingdom
Investigative Site
London, United Kingdom
Investigative Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.